p-nitrobenzyl (1R,5S,6S)-2-diphenylphosphoryloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate | 155549-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: p-nitrobenzyl (1R,5S,6S)-2-diphenylphosphoryloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate
• 英文别名: 4-nitrobenzyl (1 R ,5 R ,6 S)-2-(diphenylphosphoryloxy)-6-[(1 R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate；4-nitrobenzyl (1R,5S,6S)-2-(diphenylphosphoryloxy)-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate；4-nitrobenzyl (1R,5R,6S)-6-[(1 R)-1-hydroxyethyl]-1-methyl-2-diphenylphosphoryloxy-1-carbapen-2-em-3-carboxylate；p-nitrobenzyl (1R,5S,6S)-2-(diphenylphosphoryloxy)-6-[(R)-1-hydroxyethyl)-1-methylcarbapen-2-em-3-carboxylate；(4-nitrophenyl)methyl (4R,5S,6S)-3-diphenylphosphoryloxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
• CAS: 155549-49-8
• 化学式: C₂₉H₂₇N₂O₈P
• 分子量: 562.516
• InChiKey: DMKZERWLEGTECU-UEUXDIAVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  139
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  p-nitrobenzyl (1R,5S,6S)-2-diphenylphosphoryloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate 在 N,N-二异丙基乙胺 作用下， 以 乙酸乙酯 、 乙腈 为溶剂， 生成 p-nitrobenzyl (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(2S,4S)-2-[2-carbamoyl-1-(p-nitrobenzyloxycarbonylaminomethyl)ethyl]-N-(p-nitrobenzyloxycarbonyl)pyrrolidin-4-ylthio]-1-methyl-1-carbapen-2-em-3-carboxylate
  参考文献：
  名称：

  Aminoalkylpyrrolidinylthiocarbapenem derivatives

  摘要：

  根据您的要求，以下是化合物的翻译结果： 一种具有以下公式的化合物：##STR1## 其中R.sup.1是氢原子或甲基，R.sup.2是氢原子或负电荷，R.sup.3是氢原子、卤素原子、羟基、低级烷氧基、低级烷氧酰基、氨基、N-低级烷基氨基、N,N-二低级烷基氨基、低级烷氧酰氨基、芳氧酰氨基、(低级烷基亚磺酰基)氨基、磺酰胺氨基、氰基、硝基、--COOR.sup.4基团(其中R.sup.4是氢原子或低级烷基)或--CON(R.sup.5)R.sup.6基团(其中R.sup.5和R.sup.6可以是相同的或不同的，是氢原子或低级烷基，或者R.sup.5和R.sup.6与相邻的氮原子共同形成一个杂环组，选自包括氮杂环丙基、氮杂环丁基、吡咯烷基、哌啶基、哌嗪基、4-低级烷基哌嗪基和吗啡啉基的组中)，A是线性的或分支的低级亚烷基，X是--N(R.sup.7)R.sup.8基团(其中R.sup.7和R.sup.8可以是相同的或不同的，是氢原子或低级烷基)或--N.sup.+ (R.sup.9)(R.sup.10)R.sup.11基团(其中R.sup.9、R.sup.10和R.sup.11可以是相同的或不同的，是低级烷基)，前提是当A是线性的低级亚烷基时，R.sup.3不是氢原子；或者其药物可接受的盐或酯。

  公开号：

  US05550121A1
• 作为产物：
  描述：

  4-nitrobenzyl (1R,5R,6S)-6-[(1R)-1-hydroxyethyl]-1-methyl-2-oxo-1-carbapenam-3-carboxylate 、 氯磷酸二苯酯 在 sodium chloride 、 N,N-二异丙基乙胺 作用下， 以 异丙醚 、 乙酸乙酯 、 乙腈 为溶剂， 生成 p-nitrobenzyl (1R,5S,6S)-2-diphenylphosphoryloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate
  参考文献：
  名称：

  Carbapenem derivatives, their preparation and their use as antibiotics

  摘要：

  式(I)的化合物：其中R.sup.1x为氢或甲基，R.sup.2x为氢或可选择地取代的脂肪烃基或酰亚胺基，R.sup.3x为氢或酯基，Q.sup.x为环状或非环状含氮基团。这些化合物是强效抗生素，对脱氢肽酶I具有抗性，因此可用于治疗许多微生物感染。

  公开号：

  US05712267A1

文献信息

• 1- Methylcarbapenem derivatives
  申请人：Sankyo Company, Limited

  公开号：US06090802A1

  公开（公告）日：2000-07-18

  A 1-methylcarbapenem compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen or C.sub.1 -C.sub.4 alkyl; R.sup.2 represents hydrogen or an ester residue; and A represents a group of the formula (A1) ##STR2## wherein n is 0, 1 or 2, P is 0, 1 or 2, R.sup.3 is hydrogen or C.sub.1 -C.sub.4 alkyl and R.sup.4 is a group (Q2) ##STR3## wherein B is phenylene, phenylene(C.sub.1 -C.sub.3)alkyl, cyclohexylene, cyclohexylene(C.sub.1 -C.sub.3)alkyl or C.sub.1 -C.sub.5 alkylene, R.sup.7 is hydrogen or C.sub.1 -C.sub.4 alkyl, and R.sup.14 is a group --C(.dbd.NH)R.sup.8, wherein R.sup.8 is hydrogen or C.sub.1 -C.sub.4 alkyl or a group --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are the same or different and are hydrogen or C.sub.1 -C.sub.4 alkyl; or a pharmacologically acceptable salt thereof.

  一种由以下化学式（I）表示的1-甲基碳青霉烯类化合物：其中R.sup.1代表氢或C.sub.1 -C.sub.4烷基；R.sup.2代表氢或酯基；A代表以下化学式（A1）的基团：其中n为0、1或2，P为0、1或2，R.sup.3为氢或C.sub.1 -C.sub.4烷基，R.sup.4为基团（Q2）：其中B为苯基、苯基（C.sub.1 -C.sub.3）烷基、环己基、环己基（C.sub.1 -C.sub.3）烷基或C.sub.1 -C.sub.5烷基，R.sup.7为氢或C.sub.1 -C.sub.4烷基，R.sup.14为基团--C(.dbd.NH)R.sup.8，其中R.sup.8为氢或C.sub.1 -C.sub.4烷基或基团--NR.sup.9 R.sup.10，其中R.sup.9和R.sup.10相同或不同，为氢或C.sub.1 -C.sub.4烷基；或其药理学上可接受的盐。
• 1-methylcarbapenem derivatives
  申请人：Sankyo Company Limited

  公开号：US05977097A1

  公开（公告）日：1999-11-02

  A 1-methylcarbapenem compound represented by the following formula: ##STR1## [wherein R.sup.1 represents a hydrogen atom or a lower alkyl group, R.sup.2 represents a hydrogen atom or a lower alkyl group, R.sup.3 represents a hydrogen atom, a lower alkyl group, a lower alkyl group which has a substituent, a cycloalkyl group or a group of formula --C(.dbd.NH)R.sup.4 (in which R.sup.4 represents a hydrogen atom, a lower alkyl group or an amino group)]; or a pharmacologically acceptable salt or derivative thereof. The 1-methylcarbapenem compounds of the present invention exhibit excellent antibacterial activity and are therefore effective as a preventive or remedy of infections.

  一种1-甲基碳青霉烯化合物，其化学式如下：##STR1## [其中R.sup.1代表氢原子或低碳基，R.sup.2代表氢原子或低碳基，R.sup.3代表氢原子，低碳基，带有取代基的低碳基，环烷基或式--C(.dbd.NH)R.sup.4的基团（其中R.sup.4代表氢原子，低碳基或氨基）]；或其药理学上可接受的盐或衍生物。本发明的1-甲基碳青霉烯化合物表现出优异的抗菌活性，因此可作为预防或治疗感染的有效药物。
• Crystalline 1-methylcarbapenem derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20020128254A1

  公开（公告）日：2002-09-12

  This invention provides crystalline forms of a 1-methylcarbapenem derivative of formula (I) or of pharmaceutically acceptable salts thereof. 1 The crystalline forms of the 1-methylcarbapenem derivative exhibit excellent antibiotic activity against various bacterial strains and sufficient stability for practical use.

  本发明提供了式（I）的1-甲基碳青霉烯衍生物的晶体形式，或其药学上可接受的盐的晶体形式。1-甲基碳青霉烯衍生物的晶体形式对各种细菌菌株表现出优异的抗生素活性，并具有足够的稳定性以供实际使用。
• 1-Methylcarbapenem derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040014962A1

  公开（公告）日：2004-01-22

  1-Methylcarbapenem compounds having antibacterial activity, pharmacologically acceptable esters or salts thereof and pharmaceutical compositions (particularly antibacterial agents) containing them as an active ingredient are described. In addition, the invention includes the use of these compounds, ester derivatives or salts for the manufacture of pharmaceutical compositions, or a method for the prevention or treatment of diseases (particularly bacterial infections) by administering a pharmacologically effective amount of the compounds, ester derivatives or salts to warm-blooded animals (particularly human beings).

  本文描述了具有抗菌活性的1-甲基碳青霉烯化合物，其药理学上可接受的酯或盐以及含有它们作为活性成分的制药组合物（特别是抗菌剂）。此外，本发明包括使用这些化合物、酯衍生物或盐制造制药组合物，或通过向温血动物（特别是人类）施用药理学有效量的化合物、酯衍生物或盐来预防或治疗疾病（特别是细菌感染）的方法。
• Carbapenem derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05707987A1

  公开（公告）日：1998-01-13

  A compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a lower alkyl group, R.sup.2 is a hydrogen atom or a negative charge, R.sup.3 is a hydrogen atom or a lower alkyl group, Ar is a phenyl group, a naphthyl group or a group of: ##STR2## (wherein each of A.sub.4 and A.sub.5 is a single bond, --NHSO.sub.2 -- or the like, and Het is a pyrrolinyl group, a 1,4-diazabicyclo\x9b2.2.2!octanyl group or the like which may be substituted with a hydroxyl group, a carbamoyl lower alkyl group or the like) which may be substituted with a lower alkyl group, a lower alkylsulfamoyl group or the like which may be substituted with a hydroxyl group, a di-lower alkylsulfonyl group or the like; a hydroxyl group; a di-lower alkylsulfamoyl group or the like, each of A.sub.1, A.sub.2 and A.sub.3 is a single bond or a lower alkylene group which may be substituted with a lower alkyl group, a lower alkylsulfamoyl group or the like which may be substituted with a hydroxyl group, a di-lower alkylsulfamoyl group or the like; a pyridyl group or a pyridino group; and W is a sulfur atom, a single bond; or a pharmaceutically acceptable salt or ester; a process for its production and an antibacterial agent containing it as an active ingredient.

  化合物的结构式为：##STR1## 其中R.sup.1是氢原子或低碳基，R.sup.2是氢原子或负电荷，R.sup.3是氢原子或低碳基，Ar是苯基、萘基或：##STR2## （其中A.sub.4和A.sub.5是单键、--NHSO.sub.2--或类似物，Het是吡咯烷基、1,4-二氮杂双环\x9b2.2.2!辛基或类似物，可用羟基、氨基甲酰低碳基或类似物取代），可用低碳基、低碳基磺酰胺基或类似物取代，可用双低碳基磺酰基或类似物取代；羟基；双低碳基磺酰胺基或类似物，其中A.sub.1、A.sub.2和A.sub.3是单键或低碳亚基，可用低碳基、低碳基磺酰胺基或类似物取代，可用双低碳基磺酰胺基或类似物取代；吡啶基或吡啶酮基；W是硫原子、单键；或药学上可接受的盐或酯；一种制备它的方法和含有它作为活性成分的抗菌剂。